Overall, in preclinical models the normalization of tumor vasculature with anti-VEGF antibody can increase extravasation of adoptively transferred T cells into the tumor and to improve the clinical efficacy of adoptive cell transfer-based immunotherapy [92]. This evidence concerns the gene VEGFA and neoplasm.